Overview

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is the first-in-human study for an oral investigational compound, PF-06282999, in order to assess its safety, tolerability and pharmacokinetics in humans across a wide range of dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer